Brian Branchford, MD

Brian  Brian  profile

Brian Branchford, MD

Associate Medical Director, Associate Investigator

Hemostasis, Thrombosis and Vascular Biology

Associate Medical Director
Comprehensive Center for Bleeding Disorders, Medical Sciences Institute Versiti 

Associate Investigator
Blood Research Institute Versiti

Assistant Professor of Pediatrics
Division of Hematology/Oncology/Bone Marrow Transplant
Medical College of Wisconsin

Education and Training

Postdoctoral Training: University of Colorado School of Medicine, Pediatric Hem/Onc/BMT Fellowship & Platelet Activation Signaling, Jorge Di Paola Lab, 2018

Pediatrics Residency: Medical College of Wisconsin, VWF Genetics, Robert Montgomery Lab, 2009
MD: 
University of WIsconsin School of Medicine and Public Health, 2005

Contact Information

I am a physician scientist building an academic career in basic-translational research in non-malignant hematology, with a focus on pediatric thrombosis. The overall goal of my research is to define the role of platelet activation in thromboinflammation as a means to identify biomarkers for risk stratification, as well as potential novel approaches to thrombosis treatment or prevention.  As a research fellow and junior faculty hematologist, I studied basic/translational aspects of the mechanisms that determine platelet activation using a variety of in vitro functional assays and relevant animal models. I studied the role of the GAS6/MERTK signaling pathway in platelet activation responses and thrombus formation using pharmacologic antagonists and transgenic murine models.

I have recently studied differential expression of inflammatory cytokines and platelet activation signaling proteins from our pediatric thrombosis samples compared to healthy controls. We continue to investigate the role of inflammation-triggered platelet activation in thrombosis. My clinical research data and patient care experiences demonstrate a clear role of inflammation as a risk factor for pediatric thrombosis, while my basic science experience involved functional platelet activation assays and murine thrombosis models.  My next quest is to understand the mechanism behind inflammatory triggers of GAS6/MERTK-related platelet activation and subsequent thrombosis. My ultimate hope is that these findings can then be translated back to patient care through implementation of new anti-inflammatory thromboprophylaxis strategies. Recent advances in our understanding of the cross-talk between inflammatory mediators and the hemostatic system, as well as development of the ischemia-reperfusion injury animal model have revolutionized the field of thromboinflammation. New opportunities exist to understand the complex interplay of these systems in diseases like VTE in which the disruption of a normal physiologic process can lead to pathology. The main goal of my research is to integrate the approaches used to study platelet activation and thrombus formation with those used to study inflammation and inflammatory mediators, as well as the integration of multiple pathways in a final common disease process.

  • NIH 1 K08 HL146941-01A, The Role of Inflammation in Platelet Activation and Thrombosis (2020-2025). The goal of this project is to investigate the signaling mechaisms underlying platelet activation and thrombosis in the context of inflammation.

Stephanie Springborn
Senior Research Technologist

Click Here for a full list of publications from Dr. Brian R Branchford

Selected Publications

  1. Flood V, Gill J, Morateck P, Christopherson P, Friedman K, Haberichter S, Branchford BR, Hoffman, R, Abshire T, DiPaola J, Hoots K, Leissinger C, Lusher J, Ragni M, Shapiro A, Montgomery R. VWF exon 28 polymorphisms associated with decreased VWF:RCo/VWF:Ag ratios.  Blood.  2010: 116(2): 280-286. PMID 20231421
  2. Goldenberg N, Branchford B, Wang M, Durham J, Ray C, Manco-Johnson M. Percutaneous Mechanical and Pharmacomechanical Thrombolysis for Occlusive Deep Venous Thrombosis of the Proximal Limb in Adolescents: Findings from an Institution-Based Prospective Inception Cohort Study of Pediatric Venous Thromboembolism. J Vasc Interv Radiol 2011; 22:121–132. PMID 21216157
  3. Cooper L, Moore C, Branchford B, Greffe B, Capocelli K, Kuder A, Mehta I, Mourani P. Successful pulmonary artery embolectomy in a patient with a saddle Wilms tumor embolus.  Pediatr Blood & Cancer. 2012; 58(5):806-9. PMID 21681933
  4. Branchford BR, Mourani P, Bajaj L, Manco-Johnson M, Wang M, Goldenberg N. Risk Factors for the Development of In-Hospital Venous Thromboembolism in Children: A Case-Control Study Employing Diagnostic ValidationHaematologica. 2012; 97(4):509-15. PMID 22104422
  5. Branchford BR, Gibson E, Manco-Johnson M, Goldenberg N.  Sensitivity of discharge diagnosis ICD-9 codes for pediatric venous thromboembolism is greater than specificity, but still suboptimal for clinical research. Thromb Res. 2012; 129(5):662-3. PMID 22104422
  6. Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L, Albano E, Quinones R, Cook B, Graham DK. Alk-Positive Extranodal Anaplastic Large Cell Lymphoma with Concurrent MYC Rearrangement in a Pediatric Patient. J Pediatr Hematol Oncol. 2013; 35(5):e209-13, PMID  23619105
  7. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffman RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H Sequence Variation. Blood. 2013; 121(18)3742-4. PMID 23520336
  8. Zhang W, McIver A, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X. Discovery of Mer-specific tyrosine kinase inhibitors for the treatment and prevention of thrombosisJ Med Chem. 2013; 56(23): 9693-700. PMID 23520336
  9. Branchford BR, Ruegg K, Vilalobos-Menuey, Jacobson L, Di Paola J, Manco-Johnson M. FVIII/VWF ratio is not a reliable predictor of VWD in childrenPediatr Blood Cancer. 2014;61(5): 936-9 PMID 24281894
  10. Atchison CM, Arlikar S,  Amankwah E,  Ayala I, Barrett L, Branchford BR, Streiff M, Takemoto C, Goldenberg NA. Development of a New Risk Score for Hospital-Associated Venous Thromboembolism in Non-Critically-Ill Children: Findings from a Large Single-Institutional Case-Control Study.  J. Pediatr. 2014; 165(4): 793-8. PMID 25064163
  11. Amankwah E,  Atchison CM, Arlikar S,  Ayala I, Barrett L, Branchford BR, Streiff M, Takemoto C, Goldenberg NA. Risk Factors for Hospital-Associated Venous Thromboembolism in the Neonatal Intensive Care UnitThrombosis Research. 2014; 134(2):305-9. PMID 24953982
  12. Arlikar SJ, Atchison CM, Amankwah EK, Ayala IA, Barrett LA, Branchford BR, Streiff M, Takemoto CM, Goldenberg NA.  Development of a new risk score for hospital-associated venous thromboembolism in critically-ill children not undergoing cardiothoracic surgery. Thrombosis Research. 2015; 136(4): 717-22. PMID 25979250
  13. Mahajerin A, Branchford BR,  Amankwah EK, Raffini L, Chalmers E, van Ommen CH, Goldenberg NA. Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk assessment models.  Haematologica. 2015; 100(8): 1045-50. PMID 26001789
  14. Dittmar M, Smith N, Warren B, Clark B, Wathen B, Hammett K, Reiter P, Hilden J, Goldenberg NA, Branchford BImproved sensitivity and specificity of pediatric hospital-acquired venous thromboembolism case identification by radiographic designation. Thrombosis Research. 2017; 154: 93-95. PMID 2845607
  15. Maloney JP, Branchford BR, Brodsky GL, Cosmic MS, Calabrese DW, Aquilante CL, Maloney KW, Gonzalez JR, Zhang W, Morequ KL, Wiggings KL, Smith NL, Broeckel U, Di Paola J. The ENTPD1 promoter polymorphism 860A>G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk. FASEB J. 2017. PMID 28302652
  16. Kastelowitz N, Tamura R, Onasoga A, Stalker T, White O, Brown P, Brodsky G, Brass L, Branchford B, Di Paola J, Yin H. Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. Sci Rep 2017 Jun 27;7(1): 4275. PMID: 28655899; PMCID: PMC5487340
  17. Knight-Perry J, Branchford BR, Thornhill D, Martiniano SL, Sagel SD, Wang M. Venous Thromboembolism in Children with Cystic Fibrosis: Retrospective Incidence and Intrapopulation Risk Factors. Thromb Res. 2017 Oct; 158:161-166.  PMID: 28934665
  18. Atchison, CM, Amankwah E, Wilhelm J, Arlikar S, Branchford BR, Stock A, Streiff M, Takemoto C, Ayala I, Everett A, Stapleton G, Jacobs J, Goldenberg NA. Risk Factors for Hospital-Associated Venous Thromboembolism in Critically-Ill Children Following Cardiothoracic Surgery or Therapeutic Cardiac CatheterisationCardiol in Young. 2017 Nov 8;1-9. PMID: 29115202
  19. Branchford BR, Mahajerin A, Raffini L, Chalmers E, van Ommen CH, Chan AKC, Goldenberg NA; Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: Communication from the Subcommittee on Pediatric/Neonatal Hemostasis and Thrombosis of the International Society of Thrombosis and Hemostasis. J Thromb Haemost. 2017 Nov; 15(11):2274-2278. PMID: 29027741
  20. Jaffray J, Mahajerin A, Young G, Goldenberg N, Ji L, Sposto R, Stillings A, Krava E, Branchford BA multi-institutional registry of pediatric hospital acquired thrombosis cases: The Children’s Hospital-Acquired Thrombosis (CHAT) Project. Thromb Res. 2018 Jan;161:6-72. PMID: 29207321
  21. Newall F, Branchford B, Male C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. J Throm Haemost. 2018 Feb; 16(2): 196-208. PMID: 29316202
  22. Branchford BR, Betensky M, Goldenberg NA. Pediatric issues in thrombosis and hemostasis: The how and why of venous thromboembolism risk stratification in hospitalized childrenThromb Res. 2018 Dec; 172:190-193. PMID: 29472108
  23. Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo  P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Earp HS, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018 Feb;16(2): 352-363. PMID: 29045015 
    *Commentary in J Thromb Haemost: Cosemans JMEM. At the MERcy of platelet primers. J Thromb Haemost. 2018 Feb;16(2): 349-351.
  24. Law L, Graham D, Di Paola J, Branchford BRGAS6/TAM pathway signaling in hemostasis and thrombosis. Front Med 2018 May 9; 5:137. PMID: 29868590. PMCID: PMC5954114
  25. Branchford BR and Carpenter, S. The role of inflammation in venous thrombosis. Front Pediatr. 2018 May 23;6: 142. PMID: 29876337. PMCID: 5974100
  26. Lyren A, Coffey M, Shepherd M, Lashutka N, Muething S, the SPS Leadership Group. We will not compete on safety: How children’s hospitals have come together to hasten harm reductionJt. Comm J Qual Patient Saf. 2018 Jul;44(7):377-388. PMID: 30008350
  27. Stoffman JM, Andersson NG, Branchford B, Batt K, D’Orion R, Escuriola Ettingshausen C, Hart DP, Jiminez-Yuste V, Kavakli K, Nogami K, Ramirez C, Wu R. Common themes and challenges in hemophilia care: A multinational perspective. Hematology. 2019; 24(1): 39-48. PMID: 30073913
  28. Heizer JW, Shardt TQ, Murphy ME, Branchford BRUnfractionated heparin dosing requirements in the presence of inflammation during the first six months of life. Thromb Res. 2019 May; 177:17-22. PMID: 30844684
  29. Majtan T , Park I, Cox A, Branchford BR, di Paola J, Bublil E, Kraus JP. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine restricted diet or enzyme replacement therapy. FASEB J. 2019 Nov; 33(11): 12477-12486. PMID: 31450979
  30. Padhye K, El-Hawary R, Price V, Stevens S, Branchford B, Kulkarni K.  Development of a perioperative venous thromboembolism prophylaxis algorithm for pediatric orthopedic surgical patients. Pediatr Hematol Oncol. 2019 Dec; 23:1-10. PMID: 31868065
  31. Mahajerin A, Jaffray J, Branchford B, Stilings A, Krava E, Young G, Goldenberg N, Faustino V. Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolismJ Thromb Haemost. 2019 Dec. PMID: 31808292
  32. Goldenberg NA, Branchford BR. Commentary: Phase 3 pediatric anticoagulant era. Blood. 2020 Feb; 135(7):459-60. PMID:32197268.
    *Commentary on Brandao LR, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in childrenBlood. 2019 Dec 5: 135(7): 491-504. PMID:31805182
  33. Perez Botero J, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J; Glanzmann Thrombasthenia: genetic basis and clinical correlates. ClinGen Platelet Disorder Variant Curation Expert Panel. Haematologica. 2020 Apr 5. 105(4):888-894. PMID: 32139434
  34. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 Anticoagulation Recommendations in Children. Pediatr Blood Cancer. 2020. Sep;67(9):28485. PMID 32558124
  35. Good RJ, Levin M, Feder S, Loi MM, Kim JS, Branchford BR, Czaja AS, Carpenter TC. Accuracy of bedside ultrasound femoral vein diameter by PICU providersPediatr Crit Care Med. 2020 Dec;21(12):e1148-e1151. PMID 32639474
  36. Park I, Johnson LK, Haefner K, Cox A, Branchford BR, Cavasin M, di Paola J, Bublil E and Majtan T. Hypermethioninemia leads to increased mortality and coagulopathy in a transgenic I278T mouse model of homocystinuriaBiomedicines. 2020 Jul 24;8(8):244. PMID 32722248
  37. Jaffray J, Branchford B, Goldenberg N, Malvar J, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Sposto R, Ji L, Zakai NA, Faustino EVS, Stillings A, Krava E, Young G, Mahajerin A. Development of  a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the CHAT ConsortiumJ Pediatr. 2021 Jan;228:252-259. PMID 32920105
  38. MacNevin W, Padhye K, Price V, El-Hawary R, Branchford BR, Stevens S, Kulkarni K. Optimizing pharmacologic thromboprophylaxis use in pediatric orthopedic surgical patients through implementation of a perioperative venous thromboembolism risk screening toolPediatr Blood Cancer. 2021 Feb;68(2):e28803. PMID 33219749
  39. Ross JE, Zhang BM, Lee K, Mohan S, Branchford BR, Bray P, Dugan SN, Freson K, Heller PG, Kahr WHA, Lambert MP, Luchtman-Jones L, Luo M, Perez-Botero J, Rondina MT, Ryan G, Westbury S, Bergmeier W, Di Paola J. Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel. Blood Adv. 2021 Jan 26;5(2):414-431.  PMID 33496739
  40. Doan P, Cox A, Rao E, Branchford B. Temporal and anatomic relationship between superficial and deep vein thrombosis in childrenThromb Res. 2021 Apr;200:30-33. PMID 33529870
  41. van Ommen CH, Albisetti M, Bhatt M, Bonduel M, Branchford B, Chalmers E, Chan A, Holzhauer S, Monagle P, Nowak-Gottl U, Revel-Vilk, Sirachainan, Male C, Subcommittee on Pediatric and Neonatal Hemostasis and Thrombosis. International Pediatric Thrombosis Network to advance pediatric thrombosis research: communication from the Neonatal and Pediatric SSC of the ISTHJ Thromb Haemost. 2021 Apr;19(4):1123-1129. PMID 33792176
  42. Hart DP, Branchford BR, Hendry S, Ledniczky, Sidonio RF, Negrier C, Kim M, Rice M, Minshall M, Arce C, Prince S, Kelleher M, Lee S. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative studyOrphanet J Rare Dis. 2021 Apr 28;16(1):189. PMID: 33910590
  43. Ng CJ, Spomer N, Shearer R, LeBlanc A, Funk S, Manco-Johnson M, Branchford B, Warren B, Buckner TW, Moyer G, Wang M, Gibson E, Mashburn C. Improvements in Communication and Coordination of Care in a Hemophilia Treatment CenterActa Haematol. 2021 Apr 29:1-6. PMID: 33915533
  44. Warren BB, Chan A, Manco-Johnson M, Branchford BR, Buckner TW, Moyer G, Gibson E, Thornhill D, Wang M, Ng C. Emicizumab Initiation and Bleeding Outcomes in Hemophilia A Patients with and without Inhibitors, a Single-Center ReportRes Pract Thromb Haemost. [Accepted, In-Press June 2021].
  45. Jaffray J, Mahajerin A, Branchford B,  Nguyen ATH, Faustino EVS, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Zakai NA, Stillings A, Krava E, Amankwah E, Young G, Goldenberg NA. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report from the CHAT Consortium. Pediatr Crit Care Med. [Accepted, In-Press July 2021].

Invited Reviews and Editorials

  1. Branchford BR, Di Paola J. Making a diagnosis of von Willebrand Disease. American Society of Hematology Education Program Book, 2012; 2012:161-7.  PMID: 23233576
  2. Branchford BR, Monahan PE, Di Paola J. New developments in treatment of pediatric hemophilia and bleeding disorders. Curr Opin Pediatr. 2013; 25(1):23-30. PMID: 23274430
  3. Branchford B. Clinical and financial impact of HACs: a commentary on clinical and financial costs of hospital-acquired conditions. Transl Pediatr. 2015; 4(4):331-3. PMID 26835397
  4. Branchford BR, Ng CJ, Neeves KB, Di Paola J. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. Thrombosis Research. 2015; 136(1): 13-9. PMID: 26014643
  5. Branchford BR, Jaffray J, Mahajerin A. Editorial: Pediatric Venous Thromboembolism.  Front Pediatr. 2018; 6: 269. PMID: 30320050. PMCID: PMC6170657
 
Thrombosis & Hemostasis
We study the properties of blood that cause it to clot. Our findings help to treat diseases that cause blood clots or excessive bleeding.
 
Join Versiti Blood Research Institute
Versiti Blood Research Institute, located in Milwaukee, Wisconsin, includes basic and clinical researchers in a variety of blood health fields.
 
Our Experts
Research investigators, postdoctoral fellows and laboratory staff at Versiti Blood Research Institute and Diagnostic Laboratories.
 
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.